3 Injectable and Contract Formulation Stocks With a Strong Future Roadmap: Caplin Point Laboratories, Venus Remedies and Syncom Formulations (India)

Injectable and contract formulation stocks give investors exposure to smaller drug makers that supply injectables and make medicines for other pharma firms. Results depend on approvals, pricing and plant compliance, which is why margins and execution matter as much as headline growth.

This list covers three small pharma formulation stocks: Caplin Point Laboratories for injectable and generic formulations for Latin America and other markets, Venus Remedies for injectables and critical care medicines and Syncom Formulations (India) for contract manufacturing of formulations. Every figure comes from the latest reported financials and the 6 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Injectable and Contract Formulation Stocks?

Injectable and contract formulation stocks are shares of companies that make injectable medicines, generic formulations and contract-made drugs for pharma partners. Results depend on product approvals, export pricing, plant compliance and operating margin, so a deepening product list and clean plants separate the stronger names.

Injectable and Contract Formulation Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three injectable and contract formulation stocks as of the 6 October 2026 close.

Among small pharma formulation stocks, all three trade below their industry P/E multiples.

Why Do Injectable and Contract Formulation Stocks Have a Strong Roadmap in India?

Injectable and contract formulation stocks have a strong roadmap in India because injectables face less competition than tablets, global buyers want diversified suppliers and contract manufacturing is growing. Three drivers stand out.

• Injectable demand: Hospitals need steady supplies of injectable medicines.
• Diversified supply: Global buyers add Indian suppliers to cut risk.
• Contract manufacturing: Pharma firms outsource more production.

Caplin Point Laboratories: Injectables for Latin America Anchor the Roadmap

Caplin Point's roadmap rests on injectable and generic formulations for Latin America and other markets, with new approvals and a debt-free balance sheet supporting growth.

Revenue grew from Rs 1,308.16 crore in FY22 to Rs 2,302.73 crore in FY26, a 76.0% rise, and FY26 revenue was 13.2% higher than FY25. FY26 net profit rose 20.1% to Rs 649.73 crore. Over four years, net profit rose from Rs 308.45 crore in FY22 to Rs 649.73 crore. In Q1 FY27, revenue grew 20.7% to Rs 643.91 crore, and net profit rose 18.8% to Rs 179.09 crore. Operating margin was 40.07% in FY26 and 40.47% in Q1 FY27 against 39.38% a year earlier.

Debt to equity is 0.00 and return on equity is 17.88%. FY26 operating cash flow was Rs 523.24 crore against capital expenditure of Rs 248.13 crore. Caplin Point paid a dividend of Rs 8 per share for FY26, a yield of 0.30%. At a P/E of 30.04 against an industry P/E of 37.19, the stock trades below its industry multiple.

What to watch: FY26 net profit growth of 20.1% needs to continue through the next quarters to support a P/E of 30.04.

Venus Remedies: Injectables and Critical Care Medicines Drive the Pipeline

Venus Remedies' roadmap rests on injectables and critical care medicines, with export approvals and new products supporting revenue.

Revenue grew from Rs 608.49 crore in FY22 to Rs 782.18 crore in FY26, a 28.5% rise, and FY26 revenue was 16.9% higher than FY25. FY26 net profit rose 126.9% to Rs 102.79 crore. Over four years, net profit rose from Rs 40.72 crore in FY22 to Rs 102.79 crore. In Q1 FY27, revenue grew 29.1% to Rs 181.48 crore, and net profit rose 139.3% to Rs 22.97 crore.

Debt to equity is 0.02 and return on equity is 15.49%. FY26 operating cash flow was Rs 155.77 crore against capital expenditure of Rs 37.70 crore. At a P/E of 20.46 against an industry P/E of 37.19, the stock trades below its industry multiple.

What to watch: A market cap of Rs 2,378 Cr means the share price can swing sharply.

Syncom Formulations (India): Contract Manufacturing of Formulations Builds the Next Leg

Syncom's roadmap rests on contract manufacturing of formulations, with larger orders from pharma partners supporting volumes.

Revenue grew from Rs 231.66 crore in FY22 to Rs 520.51 crore in FY26, a 124.7% rise, and FY26 revenue was 7.9% higher than FY25. FY26 net profit rose 54.6% to Rs 76.44 crore. Over four years, net profit rose from Rs 19.79 crore in FY22 to Rs 76.44 crore. In Q1 FY27, revenue grew 8.5% to Rs 133.36 crore, and net profit rose 57.8% to Rs 24.85 crore. Operating margin was 22.24% in FY26 and 27.12% in Q1 FY27 against 18.72% a year earlier.

Debt to equity is 0.00 and return on equity is 18.42%. FY26 operating cash flow was Rs 58.08 crore against capital expenditure of Rs 11.67 crore. Syncom Formulations paid a dividend of Rs 0.1 per share for FY26, a yield of 0.43%. At a P/E of 25.54 against an industry P/E of 37.19, the stock trades below its industry multiple.

What to watch: FY26 revenue growth was only 7.9%, and a market cap of Rs 2,185 Cr means the share price can swing sharply.

Best Injectable and Contract Formulation Stocks in India: Caplin Point vs Venus Remedies vs Syncom Formulations on Key Financials

Among the best injectable and contract formulation stocks in India, Caplin Point leads on FY26 operating margin; Venus Remedies leads on Q1 FY27 revenue growth and the lowest P/E; Syncom Formulations leads on five-year revenue growth and return on equity. The table puts the numbers side by side.

Formulation earnings follow approvals and pricing, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Injectable and Formulation Maker Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen injectable and contract formulation stocks and shortlist injectable and formulation maker stocks to buy.

1. Compare each stock's P/E with its industry P/E, which is 37.19 for all three here.
2. Track operating margin across several quarters, because input costs can move faster than prices.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these injectable and contract formulation stocks

Risks to Consider Before Investing in Injectable and Contract Formulation Stocks

• Pricing and regulation: Price cuts and plant inspections can hit margins.
• Market concentration: Caplin Point relies heavily on Latin American markets.
• Small size: Venus Remedies and Syncom have market caps of Rs 2,378 Cr and Rs 2,185 Cr, so shares can swing sharply.
• Lumpy growth: Venus Remedies' FY26 net profit more than doubled from a modest base, which may not repeat.

Download the Univest iOS App or Univest Android App to track Caplin Point, Venus Remedies and Syncom Formulations live.

Final Take: Which Stock Has the Strongest Roadmap?

These three injectable and formulation maker stocks cover injectables for Latin America, injectables and critical care medicines, and contract-made formulations. Caplin Point leads on FY26 operating margin; Venus Remedies leads on Q1 FY27 revenue growth and the lowest P/E; Syncom Formulations leads on five-year revenue growth and return on equity.

Across small pharma formulation stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the injectable and formulation maker stocks to buy discussed here.

FAQs on Injectable and Contract Formulation Stocks

Which are the best injectable and contract formulation stocks in India with a strong roadmap?

Ans. Caplin Point Laboratories, Venus Remedies and Syncom Formulations (India) stand out for their roadmaps in injectables and contract-made medicines. FY26 revenue growth was 13.2% at Caplin Point, 16.9% at Venus Remedies and 7.9% at Syncom Formulations, and return on equity ranges from 15.49% to 18.42%.

Is Caplin Point Laboratories a good stock to buy now?

Ans. Caplin Point Laboratories has a debt to equity ratio of 0.00, a return on equity of 17.88% and a P/E of 30.04 against an industry P/E of 37.19. Pricing, regulation and market concentration move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Caplin Point, Venus Remedies and Syncom Formulations?

Ans. The P/E ratio is 30.04 for Caplin Point (industry 37.19), 20.46 for Venus Remedies (industry 37.19) and 25.54 for Syncom Formulations (industry 37.19). All three trade below the industry multiple.

Which of these injectable and contract formulation stocks has the highest return on equity?

Ans. Syncom Formulations (India) has the highest return on equity at 18.42%, followed by Caplin Point Laboratories at 17.88% and Venus Remedies at 15.49%.

What are the risks of investing in injectable and contract formulation stocks?

Ans. The main risks are pricing and regulatory checks, market concentration at one firm, small company size and uneven growth at another. Venus Remedies' FY26 net profit more than doubled from a modest base.

How did Caplin Point, Venus Remedies and Syncom Formulations perform in Q1 FY27?

Ans. Caplin Point Laboratories reported revenue of Rs 643.91 crore, up 20.7% year on year, and net profit rose 18.8% to Rs 179.09 crore. Venus Remedies reported revenue of Rs 181.48 crore, up 29.1% year on year, and net profit rose 139.3% to Rs 22.97 crore. Syncom Formulations (India) reported revenue of Rs 133.36 crore, up 8.5% year on year, and net profit rose 57.8% to Rs 24.85 crore.

Do injectable and contract formulation stocks pay dividends?

Ans. Dividend payouts differ across the three companies. The dividend yield is 0.30% for Caplin Point, 0.56% for Venus Remedies and 0.43% for Syncom Formulations, based on dividends declared for FY26.

How can I invest in injectable and contract formulation stocks in India?

Ans. You can buy injectable and contract formulation stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.